Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)

NCT04449861 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04449861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04449861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 7, 2020
Completion date
March 30, 2023
Enrollment
166 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma extensive disease